1-2 of 2
Sergio Fazio
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Risk of Incident Diabetes Related to Lipoprotein(a), LDL Cholesterol, and Their Changes With Alirocumab: Post Hoc Analyses of the ODYSSEY OUTCOMES Randomized Trial

Free
Gregory G. Schwartz, Michael Szarek, J. Wouter Jukema, Christa M. Cobbaert, Esther Reijnders, Vera A. Bittner, Markus Schwertfeger, Deepak L. Bhatt, Sergio Fazio, Genevieve Garon, Shaun G. Goodman, Robert A. Harrington, Harvey D. White, Philippe Gabriel Steg
Journal: Diabetes Care
Diabetes Care 2025;48(4):596–604
https://doi.org/10.2337/dc24-2110
Published: 06 February 2025
View articletitled, Risk of Incident Diabetes Related to Lipoprotein(a), LDL Cholesterol, and Their Changes With Alirocumab: Post Hoc Analyses of the ODYSSEY OUTCOMES Randomized Trial
Open the PDF for Risk of Incident Diabetes Related to Lipoprotein(a), LDL Cholesterol, and Their Changes With Alirocumab: Post Hoc Analyses of the ODYSSEY OUTCOMES Randomized Trial in another window
Journal Articles

Effect of Extended-Release Niacin on New-Onset Diabetes Among Hyperlipidemic Patients Treated With Ezetimibe/Simvastatin in a Randomized Controlled Trial

Open Access
John R. Guyton, MD, Sergio Fazio, MD, Adeniyi J. Adewale, PHD, Erin Jensen, MS, Joanne E. Tomassini, PHD, Arvind Shah, PHD, Andrew M. Tershakovec, MD
Journal: Diabetes Care
Diabetes Care 2012;35(4):857–860
https://doi.org/10.2337/dc11-1369
Published: 13 March 2012
View articletitled, Effect of Extended-Release Niacin on New-Onset Diabetes Among Hyperlipidemic Patients Treated With Ezetimibe/Simvastatin in a Randomized Controlled Trial
Open the PDF for Effect of Extended-Release Niacin on New-Onset Diabetes Among Hyperlipidemic Patients Treated With Ezetimibe/Simvastatin in a Randomized Controlled Trial in another window
Includes: Supplementary data